Essex Investment Management Co. LLC increased its position in Recro Pharma, Inc. (NASDAQ:REPH) by 40.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 93,199 shares of the specialty pharmaceutical company’s stock after buying an additional 26,785 shares during the period. Essex Investment Management Co. LLC owned 0.49% of Recro Pharma worth $837,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Recro Pharma by 14.2% during the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock valued at $4,501,000 after purchasing an additional 79,520 shares during the last quarter. OxFORD Asset Management LLP grew its holdings in Recro Pharma by 364.3% during the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 159,619 shares during the last quarter. Northern Trust Corp grew its holdings in Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the last quarter. State Street Corp acquired a new position in Recro Pharma during the second quarter valued at approximately $1,047,000. Finally, Dimensional Fund Advisors LP grew its holdings in Recro Pharma by 787.4% during the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after purchasing an additional 114,960 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.
Recro Pharma, Inc. (REPH) opened at $8.62 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma, Inc. has a twelve month low of $5.81 and a twelve month high of $10.17.
Several equities research analysts have recently issued reports on REPH shares. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Wednesday, August 16th. Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Monday, July 31st. Finally, Piper Jaffray Companies set a $11.00 target price on Recro Pharma and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Recro Pharma presently has an average rating of “Buy” and an average target price of $12.63.
ILLEGAL ACTIVITY WARNING: This news story was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.truebluetribune.com/2017/11/14/recro-pharma-inc-reph-shares-bought-by-essex-investment-management-co-llc.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.